Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

York Teaching Hospital Signs Up BD FocalPoint™

Published: Friday, September 13, 2013
Last Updated: Friday, September 13, 2013
Bookmark and Share
Fifth NHS cytology centre adopts Source BioScience’s automated screening technology.

Source BioScience has announced that, following a competitive tender process, York Teaching Hospital NHS Foundation Trust (‘York’) has renewed its contract for liquid based cytology (‘LBC’).

York has also committed to implementing Source BioScience’s automated cervical cancer screening BD FocalPoint™ technology.

The agreement is worth a total of £1.3 million over three years and was commenced on 1 April 2013.

Source BioScience provides customers with a unique and complete solution for cervical cancer screening, including HPV testing, from sample collection, processing, imaging and diagnostic testing.

The newest development in the screening process is BD FocalPoint™, the only automated technology for cervical cancer screening approved for use by the NHS, which is distributed in the UK by Source BioScience alone.

The BD FocalPoint™ technology is able to analyze and identify up to 25% of screening samples that can be reported as “No Further Review” (NFR) requiring no primary manual examination.

With over 3.9 million tests being undertaken across England and Wales during 2011-2012, the BD FocalPoint™ technology represents a significant reduction in laboratory workload and the need for additional staffing and outsourcing.

York Teaching Hospital is the fifth NHS cytology centre in England and Wales to adopt Source BioScience’s BD FocalPoint™ and the 7th platform to be placed within the NHS. This contract increases the aggregate value of the automated imaging business to Source BioScience to £0.6 million per annum over the next three years.

Trevor Hair, Head Biomedical Scientist for Cytology at York, said: “We’re delighted to have secured this contract on behalf of the Trust. In taking on additional cervical screening work from Hull and East Riding, our workload will increase from around 54,000 to 90,000 samples a year. The contract will make York laboratory the single cervical cytology screening provider for North and East Yorkshire and mean that all women who require a cervical screening test will now be able to have their samples examined at a single laboratory that will utilize the latest technology available in the UK.”

Dr Nick Ash, CEO at Source BioScience, commented: “Since the NHS published its implementation guidelines in July 2011, there has been significant interest from NHS Trusts in the BD FocalPoint™ technology. The renewal of the York contract and the adoption of the technology by another NHS Trust, demonstrates the determination to provide better timeliness and efficiencies for cervical cancer screening. This technology is an important growth driver for our business and we aim to win more contracts during 2013.”

During 2012, over two million women had their cervical cancer screening test undertaken using the technology provided by Source BioScience, which represents over 50% of all testing in England and Wales.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
First Entirely 3D-printed Organ-on-a-Chip with Integrated Sensors
New approach to manufacturing may allow researchers to rapidly design organs-on-chips that match the properties of a specific disease or individual patient's cells.
Bacterial Genes Boost Current in Human Cells
Borrowing and tweaking bacterial genes to enhance electrical activity might treat heart, nervous system injury.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
Untangling a Cause of Memory Loss in Neurodegenerative Diseases
The mouse study identifies a possible therapeutic target for a family of disorders.
New Pathway for COPD Biomarker Development
A study from Philip Morris International has highlighted multi-lipid profiling as a potential new pathway for COPD biomarker development.
Stiffening a Blow to Cancer Cells
Researchers develop a way to predict how a tumor tissue's physical properties affect its response to chemotherapy drugs.
Anti-Cancer Drug Uses Tumour mRNA to Identify Responders
Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify patients who will respond to the drug.
New Strategy for Choosing Cancer Drugs
Device can predict tumor responses by measuring cell growth after drug exposure.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos